Streetbeat News

CLRB

Cellectar Biosciences, Inc.

https://www.cellectar.com

Industry

Biotechnology

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Cellectar Biosciences has announced a plan to restate its financials, delaying its 10-Q filing for the second quarter of 2024. Consequently, the company received a non-compliance notification from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 7:38 am

Cellectar Biosciences announced that its cash balance of $25.9M as of June 30, 2024, combined with $19.4M raised in July, is sufficient to fund its basic budgeted operations into the second quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:42 am

U.S. stocks traded slightly higher with the Dow Jones gaining over 50 points. Coca-Cola reported strong Q2 results and raised its FY24 forecast. Azitra, Adial Pharmaceuticals, and Frequency Electronics saw significant stock price increases, while Jaguar Health, TransCode Therapeutics, and Cellectar Biosciences experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 6:32 pm

Comcast Corporation (NASDAQ:CMCSA) shares fell 6.1% after reporting worse-than-expected Q2 sales results. Other notable stock movements include Azitra, Inc. (NYSE:AZTR) jumping 529% due to a new patent, and Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) rising 148% after advancing a study. General Motors Company (NYSE:GM) fell 6.1% after delaying EV projects.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 5:21 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 100 points. GE Aerospace reported better-than-expected Q2 earnings and raised its FY24 outlook. Azitra, Adial Pharmaceuticals, and Frequency Electronics saw significant stock price increases, while Jaguar Health, TransCode Therapeutics, and Cellectar Biosciences experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 4:03 pm

Cellectar Biosciences Inc. (NASDAQ:CLRB) stock is trading lower despite meeting the primary endpoint in its CLOVER WaM pivotal study for relapsed/refractory Waldenstrom’s macroglobulinemia. The study showed an overall response rate of 80% and a major response rate of 56.4%, exceeding the primary endpoint of 20% MRR. The company plans to file an FDA marketing application in Q4 2024.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 2:49 pm

Cellectar Biosciences shares are trading lower following the announcement of results from its CLOVER WaM pivotal study evaluating iopofosine I 131.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:48 am

Cellectar Biosciences' Iopofosine I 131 has exceeded its primary endpoint in a pivotal study for Waldenstrom's Macroglobulinemia, achieving a 56.4% major response rate and a 98.2% disease control rate in heavily pretreated patients.

Portfolio Pulse from charles@benzinga.com

July 23, 2024 | 10:51 am

Cellectar Biosciences shares are trading higher following the company's announcement regarding the exercise of Tranche B warrants and the purchase of new warrants.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 4:46 pm

Cellectar Biosciences (NASDAQ:CLRB) has generated $19.4M through the exercise of Tranche B warrants and the purchase of new warrants, with the potential to generate an additional $73.3M if the new warrants are exercised.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 10:52 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.